MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma

Cancer Prevention Research

Volumn 6, Issue 3, 2013, Pages 196-205

  Wu, Xifeng ^a   Ajani, Jaffer A ^a   Gu, Jian ^a   Chang, David W ^a   Tan, Weiqi ^a   Hildebrandt, Michelle A T ^a   Huang, Maosheng ^a   Wang, Kenneth K ^b   Hawk, Ernest ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 133A; MICRORNA 17 92; MICRORNA 203; MICRORNA 205; MICRORNA 223; MICRORNA 23B; MICRORNA 25; MICRORNA 301B; MICRORNA 375; MICRORNA 618; PROTEIN; PROTEIN LET 7C; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER STAGING; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DOWN REGULATION; ESOPHAGEAL ADENOCARCINOMA; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; CLUSTER ANALYSIS; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PRECANCEROUS CONDITIONS; REAL-TIME POLYMERASE CHAIN REACTION; TRANSCRIPTOME;

EID: 84877308966     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-12-0276     Document Type: Article

References (50)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Globalcancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
3. Hongo M, Nagasaki Y, Shoji T. Epidemiology of esophageal cancer: Orient to Occident. Effects of chronology, geography and ethnicity. J Gastroenterol Hepatol 2009;24:729-35.
4. Pera M. Recent changes in the epidemiology of esophageal cancer. Surg Oncol Oxford 2001;10:81-90. (Pubitemid 34032024)
5. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005;97:142-6. (Pubitemid 40277094)
6. DeMeester SR. Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment. Ann Surg Oncol 2006; 13:12-30. (Pubitemid 43117641)
7. Lagergren J. Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk? Gut 2005;54 Suppl 1:i1-5. (Pubitemid 40293002)
8. Howlader NA, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, et al. SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD. Available from: http://seercancergov/csr/1975-2008/, based on November 2010SEERdata submission, posted to the SEER web site, 2011, accessed June 20, 2012.
9. Cameron AJ, Lomboy CT. Barrett's esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology 1992;103:1241-5.
10. Wild CP, Hardie LJ. Reflux, Barrett's oesophagus and adenocarcinoma: burning questions. Nat Rev Cancer 2003;3:676-84. (Pubitemid 37328822)
11. Shaheen NJ, Richter JE. Barrett's oesophagus. Lancet 2009;373: 850-61.
12. Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008;103:788-97. (Pubitemid 351406009)
13. Gu J, Ajani JA, Hawk ET, Ye Y, Lee JH, Bhutani MS, et al. Genome-Wide catalogue of chromosomal aberrations in Barrett's esophagus and esophageal adenocarcinoma: a high-density single nucleotide polymorphism array analysis. Cancer Prev Res 2010;3: 1176-86.
14. Schnell TG, Sontag SJ, Chejfec G, Aranha G, Metz A, O'Connell S, et al. Long-term nonsurgical management of Barrett's esophagus with highgrade dysplasia. Gastroenterology 2001;120:1607-19. (Pubitemid 32523480)
15. Bhat S, Coleman HG, Yousef F, Johnston BT, McManus DT, Gavin AT, et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. J Natl Cancer Inst 2011;103:1049-57.
16. Montgomery E, Bronner MP, Goldblum JR, Greenson JK, Haber MM, Hart J, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol 2001;32:368-78. (Pubitemid 32378298)
17. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-66. (Pubitemid 44629897)
18. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005;433:769-73. (Pubitemid 40292988)
19. Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu Rev Med 2009;60:167-79.
20. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435:834-8. (Pubitemid 40839735)
21. Fabbri M, Croce CM, Calin GA. MicroRNAs. Cancer J 2008;14:1-6.
22. Dijckmeester WA, Wijnhoven BPL, Watson DI, Leong MP, Michael MZ, Mayne GC, et al. MicroRNA-143 and-205 expression in neosquamous esophageal epithelium following argon plasma ablation of Barrett's esophagus. J Gastrointest Surg 2009;13:846-53.
23. Kan T, Meltzer SJ. MicroRNAs in Barrett's esophagus and esophageal adenocarcinoma. Curr Opin Pharmacol 2009;9:727-32.
24. Maru DM, Singh RR, Hannah C, Albarracin CT, Li YX, Abraham R, et al. MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus. Am J Pathol 2009;174:1940-8.
25. Yang H, Gu J, Wang KK, Zhang W, Xing J, Chen Z, et al. MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma. Clin Cancer Res 2009;15:5744-52.
26. Wijnhoven BPL, Hussey DJ, Watson DI, Tsykin A, Smith CM, Michael MZ, et al. MicroRNA profiling of Barrett's oesophagus and oesophageal adenocarcinoma. Br J Surg 2010;97:853-61.
27. Bansal A, Lee IH, Hong X, Anand V, Mathur SC, Gaddam S, et al. Feasibility of mcroRNAs as biomarkers for Barrett's esophagus progression: a pilot cross-sectional, phase 2 biomarker study. Am J Gastroenterol 2011;106:1055-63.
28. Fassan M, Volinia S, Palatini J, Pizzi M, Baffa R, De Bernard M, et al. MicroRNA expression profiling in human Barrett's carcinogenesis. Int J Cancer 2011;129:1661-70.
29. Gu J, Wang Y, Wu X. MicroRNA in the pathogenesis and prognosis of esophageal cancer. Curr Pharm Des 2012 Sep 25. [Epub ahead of print].
30. Olive V, Jiang I, He L. mir-17-92, a cluster of miRNAs in the midst of the cancer network. Int J Biochem Cell Biol 2010;42:1348-54.
31. Nancarrow DJ, Clouston AD, Smithers BM, Gotley DC, Drew PA, Watson DI, et al. Whole genome expression array profiling highlights differences in mucosal defense genes in Barrett's esophagus and esophageal adenocarcinoma. PLoS One 2011;6:e22513.
32. Leidner RS, Ravi L, Leahy P, Chen Y, Bednarchik B, Streppel M, et al. The microRNAs, MiR-31 and MiR-375, as candidate markers in Barrett's esophageal carcinogenesis. Genes Chromosomes Cancer 2012;51:473-9.
33. Mathe EA, Nguyen GH, Bowman ED, Zhao Y, Budhu A, Schetter AJ, et al. MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res 2009;15:6192-200.
34. Fazi F, Rosa A, Fatica A, Gelmetti V, De Marchis ML, Nervi C, et al. A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis. Cell 2005;123:819-31. (Pubitemid 41721029)
35. Earle JS, Luthra R, Romans A, Abraham R, Ensor J, Yao H, et al. Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma. J Mol Diagn 2010;12:433-40.
36. Laios A, O'Toole S, Flavin R, Martin C, Kelly L, Ring M, et al. Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer 2008;7:35.
37. Li D, Liu X, Lin L, Hou J, Li N, Wang C, et al. MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J Biol Chem 2011;286: 36677-85.
38. Sun D, Lee YS, Malhotra A, Kim HK, Matecic M, Evans C, et al. miR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation. Cancer Res 2011;71: 1313-24.
39. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009;458:762-5.
40. Tong AW, Fulgham P, Jay C, Chen P, Khalil I, Liu S, et al. MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther 2009;16:206-16.
41. Castilla MA, Moreno-Bueno G, Romero-Perez L, Van De Vijver K, Biscuola M, Lopez-Garcia MA, et al. Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma. J Pathol 2011;223:72-80.
42. Zhang H, Hao Y, Yang J, Zhou Y, Li J, Yin S, et al. Genome-wide functional screening of miR-23b as a pleiotropic modulator suppressing cancer metastasis. Nat Commun 2011;2:554.
43. Majid S, Dar AA, Saini S, Arora S, Shahryari V, Zaman MS, et al. MicroRNA-23b represses proto-oncogene Src kinase, functions as a methylation-silenced tumor suppressor with diagnostic and prognostic significance in prostate cancer. Cancer Res 2012;72: 6435-46.
44. Wang YX, Zhang XY, Zhang BF, Yang CQ, Chen XM, Gao HJ. Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis. J Dig Dis 2010;11:50-4.
45. Abdalla MA, Haj-Ahmad Y. Promising candidate urinary MicroRNA biomarkers for the early detection of hepatocellular carcinoma among high-risk hepatitis C virus Egyptian patients. J Cancer 2012;3:19-31.
46. Nasser MW, Datta J, Nuovo G, Kutay H, Motiwala T, Majumder S, et al. Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem 2008;283: 33394-405.
47. Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y, et al. miR-145, miR-133a and miR-133b: tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer 2010;127:2804-14.
48. Kawakami K, Enokida H, Chiyomaru T, Tatarano S, Yoshino H, Kagara I, et al. The functional significance of miR-1 and miR-133a in renal cell carcinoma. Eur J Cancer 2012;48:827-36.
49. Suzuki S, Yokobori T, Tanaka N, Sakai M, Sano A, Inose T, et al. CD47 expression regulated by the miR-133a tumor suppressor is a novel prognostic marker in esophageal squamous cell carcinoma. Oncol Rep 2012;28:465-72
50. Nohata N, Hanazawa T, Kikkawa N, Mutallip M, Fujimura L, Yoshino H, et al. Caveolin-1 mediates tumor cell migration and invasion and its regulation by miR-133a in head and neck squamous cell carcinoma. Int J Oncol 2011;38:209-17.